SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SENIOR* Trial – Shortened DAPT Regimen, Elderly Patients and SYNERGY Bioabsorbable Polymer (BP) Stent 

SYNERGY BP-DES was intentionally designed with a fast-absorbing polymer for early healing. SENIOR Trial is studying 1-month DAPT in stable elderly patients and 6-month DAPT in unstable elderly patients undergoing PCI with the SYNERGY BP-DES or REBEL™ BMS. 

The SYNERGY BP-DES showed superior results versus BMS in elderly patients that received a shortened DAPT** regimen in the SENIOR Trial1.

SENIOR is a multicenter, randomized trial studying 1,200 patients age 75 or older with coronary artery disease; 596 received a SYNERGY BP-DES and 605 received a REBEL BMS.

Nearly identical DAPT duration in both arms of the study1

 

SENIOR Trial Data in 1-month and 6-month DAPT Cohorts

SYNERGY BP-DES reported significantly lower MACCE*** at 1-year compared to the best-in-class BMS1

  • More than 50% of patients received 1-month DAPT
  • 29% reduction in MACCE with SYNERGY BP-DES.
  • ID-TLR was significantly lower (3x reduction) with SYNERGY BP-DES compared with BMS
  • The SYNERGY BP-DES continued to show exceptionally low ARC Def/Prob stent thrombosis (ST) rate of 0.5% (versus 1.4% with BMS, p=0.13).

SYNERGY BP Stent showed a 3x reduction in ID-TLR and exceptionally low ARC Def/Prob stent thrombosis1

Primary Endpoint: MACCE at 12-months

Primary Endpoint: MACCE** at 12-months

Safety Endpoints at 12-months

Safety Endpoints at 12-months
 

SENIOR Trial Safety Data in 1-month DAPT Cohort

SYNERGY BP-DES showed excellent data compared to best-in-class BMS within the 1-month DAPT cohort1,2

  • Zero ST with SYNERGY BP-DES after patient stopped DAPT at 1-month through 12-months1
    • 78% ST reduction with SYNERGY BP-DES compared to REBEL BMS
  • 34% reduction in MACCE with SYNERGY BP-DES compared to REBEL BMS2
    • 90% reduction in ID-TLR

Primary Endpoint: MACCE at 12-months

SYNERGY BP-DES showed excellent data compared to best-in-class BMS within the 1-month DAPT cohort1,2

SENIOR Trial Safety Data with SYNERGY BP-DES in 1-Month DAPT Cohort - Primary Endpoint: MACCE at 12-months

Safety Endpoints at 12-months

SYNERGY BP-DES showed excellent data compared to best-in-class BMS within the 1-month DAPT cohort1,2

SENIOR Trial Safety Data with SYNERGY BP-DES in 1-Month DAPT Cohort - Safety Endpoints at 12-months

Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
Top